What market crash? Here are 2 FTSE 100 shares I believe may continue to be successful in July

Despite the recent market crash, here are two FTSE 100 (INDEXFTSE: UKX) shares that I believe will keep doing well

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What a volatile six months it has been in broader markets. Following the bull market of January and February, the coronavirus that initially affected China became a global pandemic. As countries went into lockdowns, panic hit the markets. Yet after the market lows in March, many FTSE 100 shares had stellar run-ups in price.

Not every FTSE 100 stock has recovered fully, but there are several shares that are up considerably in 2020. It has now become a stock-pickers market. Those investors who concentrate on the new post-Covid-19 economy are likely to continue doing well in the second half of the year. Therefore, I’d like to discuss two FTSE 100 shares that are up in 2020. I believe they still deserve to be on your radar.

Highest market capitalisation in the FTSE 100

My first choice for today is pharma giant AstraZeneca (LSE: AZN), whose shares are up 13% year-to-date (YTD). The group is now the UK’s biggest company by market capitalisation. It’s worth over £111bn. Before the market crash, oil major Royal Dutch Shell was heading the list. But the downturn has pushed the share price down by over 43% so far in the year. And the company is now number eight on the list. What a change of fortunes.

AZN shares have been buoyed in part by pharmaceutical companies’ relative safety amid the health and economic effects of the pandemic. Investors are also ready to pay a premium for its portfolio of drugs. That may be why the stock price has almost doubled in the past five years. In July 2016, it was around 4,280p. Now it is hovering at 8,460p.

The group concentrates on several major disease areas, including cancer, cardiovascular, diabetes, gastrointestinal, infection, inflammation and respiratory. A wide range of pharma companies are currently racing to develop a vaccine against Covid-19 and AZN is one of the forerunners. In mid-June the pharma giant announced that (assuming a vaccine works) it would supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit.”

As a result, the share price has been reacting extremely well. If AZN shares had been your only portfolio holding, you might not have thought that there has been a market crash in 2020. Shareholders also enjoy a current dividend yield of 2.65%. 

Consumer rules

The second stock I want to highlight is consumer goods giant Reckitt Benckiser (LSE: RB). This year, RB shares are up over 21%.

I expect the volatility in the markets to continue in the coming weeks. Another market crash could also happen. Therefore I’d make defensive stocks part of any long-term portfolio. Analysts regard consumer staples companies as defensive. People continue to buy household items, cleaning products, and other essentials such as personal hygiene products, even when their salaries are shrinking. And the potential second wave of the viral outbreak means everyone must pay more attention to basic hygiene than before.

On 30 April, the group also released Q1 results and reported record quarterly sales growth. The robust results were led by increased demand for many of its hygiene products, such as Dettol and Lysol, and health products like MucinexNurofen, and VMS.

Reckitt Benckiser’s current dividend yield stands at 2.6%. The shares are expected to go ex-dividend in August. The FTSE 100 group feels to me like a must-have if you want a consumer-defensive company in your portfolio.

tezcang has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Here’s how investors can aim for £11,363 a year in passive income from £20,000 in this overlooked FTSE media gem

I think this media stock is commonly overlooked by investors looking for high passive income, but it shouldn’t be, given…

Read more »